This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Anticoagulants Market

Anticoagulants Market

Anticoagulants Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2021 to 2031

Anticoagulants Market
  • Sep-2021
  • List of Tables : 30
  • List of Figures : 83
  • 170 Pages
  • Healthcare

Market Snapshot

Fact.MR predicts the sales of anticoagulant are expected to reach US$ 30 Bn by the end of 2021. As per the study, demand will continue rising, expanding over 2x to be valued at US$ 65 Bn by the end of the 2021-2031 assessment period.

Players are increasingly utilizing internet sales channels to extend their reach while requiring less financial commitment. On the demand side, the rising incidence of heart attacks, owing to patients' unhealthy lifestyle choices, is expected to expand the patient pool for the anticoagulants market over the forecast period.

Key Points Addressed in Anticoagulant Industry Analysis

  • Market Estimates and Forecasts (2016-2031)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand Share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Anticoagulants Demand and How to Navigate
  • Recommendation on Key Winning Strategies

Know More Details About the Report

Anticoagulants Consumption Analysis 2016-2020 Vs Outlook 2021-2031

Sales of anticoagulants expanded at a CAGR of 5% across the historical period ranging from 2016 to 2020. Demand for anticoagulants has increased significantly in emerging nations, owing to the financial assistance provided by central governments to renovate healthcare facilities and improve service quality.

Leading firms are utilizing research and development operations to increase the number of pipeline medicines, recognizing the anticoagulants market's strong growth possibilities. The Global Anticoagulants Market is estimated to be worth US$ 65 Bn by 2031, expanding at an 8.04 % CAGR during the forecast period.

Surging Atrial Fibrillation Cases Spurring Anticoagulants Consumption?

The most common heart arrhythmia is atrial fibrillation. It is projected that 6-12 million individuals in the United States will have this disease by 2050, and 17.9 million people in Europe will have it by 2060. Atrial fibrillation is a substantial risk factor for ischemic stroke, causing a large economic burden as well as morbidity and death.

As per the National Center for Biotechnology Information, during 2017, over 3 million new instances of atrial fibrillation were detected globally. The 2017 estimated incidence rate (403/million inhabitants) was 31% higher than the 1997 corresponding incidence. The global prevalence of atrial fibrillation is 37,574 million instances, and it has grown by 33% in the past two decades.

The biggest burden is observed in nations with a high socio-demographic index; however the most recent growth occurred in countries with a moderate socio-demographic index. According to estimates, the absolute burden of atrial fibrillation may grow by more than 60% by 2050. Hence, all these factors contribute to the market growth during the   forecast period.

Avail customized purchase options for your needs

Country Wise Analysis

How do Anticoagulants Growth Prospects Appear in the U.S?

U.S. accounted for the biggest proportion of anticoagulants in 2020, owing to increased knowledge about the therapeutic uses of anticoagulants in disease management and the country's rising obesity prevalence. Furthermore, it has the highest obesity prevalence in the world.

According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017–2018. Obesity in the United States rose from 30.5% to 42.4% between 1999 and 2018. Based on aforementioned trends, the U.S market is expected to surge at a CAGR of 7.5% until 2031.

How big is the Anticoagulants Industry in Japan?

According to the World Bank, a projected 28% of Japan's total population is over 65 in 2020, with that figure predicted to increase to 40% by 2060. As a result, blood thinners such as Xarelto are widely recommended to the elderly for the treatment and prevention of blood clots. A market share worth 45% is expected for the Japanese market.

With an ageing population, demand for anticoagulants is strong, as they require surgical interventions for numerous chronic conditions. Geriatrics are more likely to have diseases such as venous thromboembolism, atrial fibrillation, and knee and hip replacement operations, increasing their risk of forming blood clots and, as a result, heart attacks and strokes.

Why is China an Emerging Market for Anticoagulants?

China is anticipated to expand at the highest rate throughout the projection period, clocking a CAGR exceeding 8% until 2031. High prevalence rate of cardiovascular diseases is spurring surgeries across the East Asian giant, paving way for high usage of anticoagulants.

According to the Lancet, nearly 4 million deaths occur due to CVDs in China annually. In an effort to mitigate the risk and reduce this burden, healthcare practitioners are advocating advanced surgical interventions. However, the risk of embolism arising from such surgeries has also increased, prompting usage of anticoagulants.

anticoagulants market by FactMR

Category Wise Insights

Why the Preference for NOAC/DOAC Factor X Inhibitors?

By drug class, NOAC/DOAC factor X inhibitors accounted for over 50% of total anticoagulants demand in 2019. This is attributed to increased NOAC uptake in poorer nations, as well as increased usage of NOACs over warfarin.

Furthermore, NOACs including betrixaban, rivaroxaban, apixaban, dabigatran, and edoxaban are used to treat and prevent atrial fibrillation/myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT). They possess numerous advantages over warfarin, including minimal dietary restrictions, fast start effect, predictable pharmacokinetic action, less drug and food interaction, and a shorter half-life.

Why are Hospital Pharmacies Primary Anticoagulants Distributors?

Hospital pharmacies are expected to account for 49.2% revenue share. This is because hospitals are the major sites for the diagnosis and treatment of many forms of bleeding problems.

As the volume of surgeries for various chronic conditions increase, episodes of embolisms post-surgery are increasing manifold. As a result, doctors highly recommend use of anticoagulants to prevent further complications in the patient.

An Adaptive Approach to Modern-day Research Needs

Competitive Landscape

The anticoagulants landscape is competitive and fragmented, with numerous significant competitors. As a tool to increase anticoagulant exposure, players in the anticoagulants industry are stepping forward to carry the financial burden of individuals through patient-assistance programmes.

  • In August 2020, Bristol-Myers Squibb, in alliance with Pfizer, announced that the U.S District Court upheld their composition of matter (COP) patent (US 6,967,208) and formulation patent (US 9,326,945) covering their Eliquis® Apixaban anticoagulants.
  • Likewise, in November 2020, Boehringer Ingelheim received approval from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for the use of Pradaxa® (dabigatran etexilate) for treating venous thromboembolic events and preventing its recurrence in pediatric patients below 18 years  

Report Scope



Market size value in 2021

USD 30 Billion

Market forecast value in 2031

USD 65 Billion

Growth Rate

CAGR of 8.04% from 2021 to 2031
Forecast Period 2021-2031
Historical Data Available for 2016-2020

Market Analysis

US$ Mn for Value & ‘000 Units for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia
  • New Zealand
  • Brazil
  • Mexico
  • GCC
  • Israel
  • South Africa

Key Market Segments Covered

  • Drug Class  
  • Indication
  • Route of Administration
  • Distribution Channel
  • Region

Key Companies Profiled

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Ltd.
  • Sanofi SA
  • Johnson & Johnson


Available upon Request

Have a report related query? Speak to us directly

Key Segments Covered

  • Drug Class

    • Factor X Inhibitor (NOAC/DOAC) Anticoagulants
    • Heparin Anticoagulants
    • Direct Thrombin Inhibitor Anticoagulants
    • Vitamin K Antagonist Anticoagulants
  • Indication

    • Anticoagulants for Deep Vein Thrombosis
    • Anticoagulants for Pulmonary Embolism
    • Anticoagulants for Atrial Fibrillation & Heart Attack
    • Anticoagulants for Other Indications
  • Route of Administration

    • Oral Anticoagulants
    • Injectable Anticoagulants
  • Distribution Channel

    • Anticoagulants Sales via Hospital Pharmacies
    • Anticoagulants Sales via Retail Pharmacies
    • Anticoagulants Sales via Online Pharmacies

Anticoagulants Market- Scope of Report

A recent study by Fact.MR on the anticoagulants market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering anticoagulants.

The study also provides the dynamics responsible for influencing the future status of the anticoagulants market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the anticoagulants market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of anticoagulants across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of anticoagulants during the forecast period. Price point comparison by region with global average price is also considered in the study.

Key Questions Answered in Report

  • Which are the most lucrative anticoagulants markets?
  • Which factors will impact the growth of anticoagulants market?
  • How will changing trends impact the strategies of market players?
  • How can market players capture the low-hanging opportunities across regions?
  • Which companies are leading the anticoagulants market industry?
  • What are the winning strategies of stakeholders in the market?

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Estimates at global and regional levels for anticoagulants are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global anticoagulants market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the anticoagulants market during the forecast period.

Country-specific valuation on demand for anticoagulants has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition Analysis

The report sheds light on leading manufacturers of anticoagulants, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering anticoagulants has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the anticoagulants domain. 

Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the anticoagulants industry, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

- FAQs -

According to Fact.MR, the anticoagulants industry is expected to reach US$ 30 Bn in 2021.

From 2016 to 2020, Fact.MR estimated the market for anticoagulants soared at 5% CAGR

From 2021 to 2031, anticoagulants demand is expected to surge at a CAGR exceeding 8%

Rising prevalence of atrial fibrillation and heart attacks is anticipated to increase uptake of anticoagulants

Demand for anticoagulants in the U.S is expected to surge at a CAGR of 7.5% from 2021 to 2031

Anticoagulants sales are expected to comprise 45% of the revenue share across Japan

China is anticipated to register a growth rate of over 8% across the forthcoming decade

NOAC/DOAC factor X-inhibitors are expected to be highly sought after, capturing 50% of total demand

Hospital pharmacies account for bulk of anticoagulants distribution, yielding 49.2% revenue

Need an Exclusive Report for your Unique Requirement?

Talk Show:

The Rise of Intelligent Packaging

Personalized, Connected and Sustainable

November 18, 2021 11:00-11:45 AM PST (USA & Canada)
This is a LIVE session
Future Market Insights MarketNgage Spring

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.